Kenvue Faces Pressure from TOMS Capital Investment Management
Kenvue, a consumer healthcare company, is facing pressure from TOMS Capital Investment Management to consider a sale or separation of its assets. The hedge fund has acquired a significant stake in the company, which was spun off from Johnson & Johnson in 2023.
Key Facts
- Kenvue’s stock price has been volatile, with fluctuations in recent periods.
- Analysts have predicted a potential decline in the company’s stock price.
- Evercore ISI has set a target price for Kenvue, but the exact amount is not disclosed.
Company Background
Kenvue was spun off from Johnson & Johnson in 2023. The company operates in the consumer healthcare sector.
Uncertainty Surrounding Kenvue’s Future
The situation surrounding Kenvue’s future direction is uncertain, with various stakeholders and analysts speculating about the company’s potential sale or separation of assets.